Gradalis is dedicated to developing and commercializing “molecular” based personalized therapeutics that are tumor specific, more effective and less toxic than current treatment modalities.

A Statement From Gradalis A Statement Regarding Ewing's Sarcoma Trial
Dr. Brian Daniels joins the SAB Gradalis Announces the Appointment of Dr. Brian Daniels to the Newly Formed Scientific Advisory Board
Dr. Steven Burakoff Joins Gradalis SAB Appointment of Dr. Steven Burakoff to the Gradalis Scientific Advisory Board
iC3 Life Science Summit Press Release Gradalis to Participate in 2nd Annual iC3 Life Science Summit Hosted By BioNorthTX
Bio Investor Forum Press Release Gradalis to Take Part in BIO Investor Forum in San Francisco
SAB Formation Press Release Sir Marc Feldmann to Chair Gradalis Scientific Advisory Board
Vigil®
Immunotherapies
Goal